Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of two new patent applications by the U.S. Patent Office with claims that provide further protection for the Company's lead candidate, entolimod, as both a medical radiation countermeasure and an oncology therapeutic. The allowed claims of U.S. Patent Application No. 14/828,111 expand coverage of the Company's lead agent, the flagellin-derived entolimod, as well as various other flagellin-derived agents, by providing composition of matter protection, which covers use of these various flagellin-derived agents to treat, for example, apoptosis related to radiation exposure or cancer. The allowed claims of U.S. Patent Application No. 13/979,104 focus on the entolimod oncology program and provide protection for uses of flagellin and flagellin-derived agents in the treatment of various cancers. CBLI now has 14 issued or allowed U.S. patents with composition of matter and method of use claims relating to entolimod's biodefense and oncology indications, as well as chemotherapy adjuvant and reperfusion injury indications. Additional pending U.S. and foreign patent claims include those covering other oncology and biodefense uses, as well as various compositions that expand the scope of the Company's Toll-like receptor (TLR) agonist platform. Yakov Kogan, Ph.D., Chief Executive Officer of Cleveland BioLabs, commented, "We believe the continued expansion of our patent claims for entolimod and its related derivatives strengthen our market position as a leader in the Toll-like receptor 5 (TLR5) space. With the market's increasing focus on immunotherapies for multiple indications, including oncology, CBLI has a strong and varied patent estate that underpins the Company's value."